207 related articles for article (PubMed ID: 38689295)
21. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis.
Valery PC; McPhail S; Stuart KA; Hartel G; Clark PJ; O'Beirne J; Skoien R; Rahman T; Moser C; Powell EE
Intern Med J; 2021 May; 51(5):691-698. PubMed ID: 32096890
[TBL] [Abstract][Full Text] [Related]
22. Indigenous Australian perspectives on incorporating the social determinants of health into the clinical management of type 2 diabetes.
Frier A; Devine S; McBain-Rigg KE; Barnett F; Cassady ZA; Dunning T; Reese RL
Rural Remote Health; 2021 Jun; 21(2):6352. PubMed ID: 34147059
[TBL] [Abstract][Full Text] [Related]
23. Population-level contribution of interpersonal discrimination to psychological distress among Australian Aboriginal and Torres Strait Islander adults, and to Indigenous-non-Indigenous inequities: cross-sectional analysis of a community-controlled First Nations cohort study.
Thurber KA; Brinckley MM; Jones R; Evans O; Nichols K; Priest N; Guo S; Williams DR; Gee GC; Joshy G; Banks E; Thandrayen J; Baffour B; Mohamed J; Calma T; Lovett R
Lancet; 2022 Dec; 400(10368):2084-2094. PubMed ID: 36502846
[TBL] [Abstract][Full Text] [Related]
24. Study Protocol--accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR study.
Maple-Brown LJ; Lawton PD; Hughes JT; Sharma SK; Jones GR; Ellis AG; Hoy W; Cass A; Macisaac RJ; Sinha AK; Thomas MA; Piers LS; Ward LC; Drabsch K; Panagiotopoulos S; McDermott R; Warr K; Cherian S; Brown A; Jerums G; O'Dea K
BMC Public Health; 2010 Feb; 10():80. PubMed ID: 20167129
[TBL] [Abstract][Full Text] [Related]
25. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
[TBL] [Abstract][Full Text] [Related]
26. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
[TBL] [Abstract][Full Text] [Related]
27. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38521116
[TBL] [Abstract][Full Text] [Related]
28. The Use of mHealth Apps for the Assessment and Management of Diabetes-Related Foot Health Outcomes: Systematic Review.
Sadler S; Gerrard J; Searle A; Lanting S; West M; Wilson R; Ginige A; Fang KY; Chuter V
J Med Internet Res; 2023 Oct; 25():e47608. PubMed ID: 37792467
[TBL] [Abstract][Full Text] [Related]
29. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
30. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
31. Common mental disorders among Indigenous people living in regional, remote and metropolitan Australia: a cross-sectional study.
Nasir BF; Toombs MR; Kondalsamy-Chennakesavan S; Kisely S; Gill NS; Black E; Hayman N; Ranmuthugala G; Beccaria G; Ostini R; Nicholson GC
BMJ Open; 2018 Jun; 8(6):e020196. PubMed ID: 29961007
[TBL] [Abstract][Full Text] [Related]
32. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
33. The applicability of commonly used predictive scoring systems in Indigenous Australians with sepsis: An observational study.
Hanson J; Smith S; Brooks J; Groch T; Sivalingam S; Curnow V; Carter A; Hargovan S
PLoS One; 2020; 15(7):e0236339. PubMed ID: 32697796
[TBL] [Abstract][Full Text] [Related]
34. Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gap.
Vos T; Barker B; Begg S; Stanley L; Lopez AD
Int J Epidemiol; 2009 Apr; 38(2):470-7. PubMed ID: 19047078
[TBL] [Abstract][Full Text] [Related]
35. Aboriginal and Torres Strait Islander youth suicide mortality and previous mental health, suicidality and service use in Queensland, Australia, from 2001 to 2021.
Gibson M; Leske S; Ward R; Weir B; Russell K; Kolves K
J Affect Disord; 2024 Jun; 354():55-61. PubMed ID: 38484672
[TBL] [Abstract][Full Text] [Related]
36. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
37. Community-based models of alcohol and other drug support for First Nations peoples in Australia: A systematic review.
Krakouer J; Savaglio M; Taylor K; Skouteris H
Drug Alcohol Rev; 2022 Sep; 41(6):1418-1427. PubMed ID: 35546281
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998-2004): does being Indigenous make a difference?
Moore SP; Soerjomataram I; Green AC; Garvey G; Martin J; Valery PC
Int J Public Health; 2016 May; 61(4):435-42. PubMed ID: 26427859
[TBL] [Abstract][Full Text] [Related]
39. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
